# To Establish the Safety and Effectiveness of the ALPFA GRAIL PFA System for Treating Symptomatic Benign Prostate Hyperplasia (BPH) Also Known as an Enlarged Prostate.

> **NCT07592299** · NA · NOT_YET_RECRUITING · sponsor: **ALPFA Medical** · enrollment: 250 (estimated)

## Conditions studied

- Benign Prostatic Hyperplasia (BPH)

## Interventions

- **DEVICE:** Treatment Device: The ALPFA Medical (ALPFA) GRAIL™ Pulsed Field Ablation (PFA) System
- **DEVICE:** Control Device: Sham flexible cystoscopy

## Key facts

- **NCT ID:** NCT07592299
- **Lead sponsor:** ALPFA Medical
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-08
- **Final completion:** 2032-12
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07592299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07592299, "To Establish the Safety and Effectiveness of the ALPFA GRAIL PFA System for Treating Symptomatic Benign Prostate Hyperplasia (BPH) Also Known as an Enlarged Prostate.". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT07592299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*